secukinumab (Cosentyx)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

* intravenous formulation FDA-approved

Adverse effects

Mechanism of action

More general terms

References

  1. Langley RG et al. Secukinumab in plaque psoriasis - Results of two phase three trials. N Engl J Med 2014 Jul 9 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25007392 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1314258
  2. Brooks M Medscape: FDA Clears Secukinumab (Cosentyx) for Plaque Psoriasis. http://www.medscape.com/viewarticle/838491
    FDA News Release. January 21, 2015 FDA approves new psoriasis drug Cosentyx http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm430969.htm
  3. 3.0 3.1 3.2 Kuznar W PsA Structural Damage Inhibited with Secukinumab - Loading dose appears to improve outcomes, researchers say. MedPage Today. Nov 9, 2017 https://www.medpagetoday.com/meetingcoverage/acr/69156
    Mease PJ et al Subcutaneous Secukinumab Inhibits Radiographic Progression in Psoriatic Arthritis: Primary Results from a Large Randomized, Controlled, Double-Blind Phase 3 Study American College of Rheumatology (ACR) 2017; Abstract 17L.
  4. 4.0 4.1 Pavelka K, Kivitz A, Dokoupilova E et al Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017 Dec 22;19(1):285. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29273067 Free PMC Article
  5. 5.0 5.1 5.2 5.3 Medical Knowledge Self Assessment Program (MKSAP) 18, 19 American College of Physicians, Philadelphia 2018, 2022
  6. 6.0 6.1 Novartis. Oct 23, 2023 FDA approves Novartis Cosentyx as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade. https://www.novartis.com/us-en/news/media-releases/fda-approves-novartis-cosentyx-first-new-biologic-treatment-option-hidradenitis-suppurativa-patients-nearly-decade